161 related articles for article (PubMed ID: 37341158)
21. Thromboembolic and bleeding complications in patients with oesophageal cancer.
Mulder FI; Hovenkamp A; van Laarhoven HWM; Büller HR; Kamphuisen PW; Hulshof MCCM; van Berge Henegouwen MI; Middeldorp S; van Es N
Br J Surg; 2020 Sep; 107(10):1324-1333. PubMed ID: 32424862
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
[TBL] [Abstract][Full Text] [Related]
23. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer.
Qureshi MM; Lin Y; Moeller AR; Yan SX; Dyer MA; Suzuki K; Everett P; Litle V; Truong MT; Mak KS
J Surg Oncol; 2023 Oct; 128(5):781-789. PubMed ID: 37288789
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
[TBL] [Abstract][Full Text] [Related]
25. ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Zanoni A; Verlato G; Giacopuzzi S; Motton M; Casella F; Weindelmayer J; Ambrosi E; Di Leo A; Vassiliadis A; Ricci F; Rice TW; de Manzoni G
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):998-1004. PubMed ID: 27480358
[TBL] [Abstract][Full Text] [Related]
26. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
[TBL] [Abstract][Full Text] [Related]
27. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
28. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
[TBL] [Abstract][Full Text] [Related]
29. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
[TBL] [Abstract][Full Text] [Related]
30. Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Kobayashi K; Kanetaka K; Yoneda A; Kobayashi S; Maruya Y; Isagawa Y; Yoshimoto T; Migita K; Kawaguchi Y; Kuba S; Morita M; Okada S; Kosaka T; Yamaguchi S; Inoue Y; Adachi T; Hidaka M; Torashima Y; Ito S; Takatsuki M; Eguchi S
J Gastrointest Cancer; 2021 Jun; 52(2):582-592. PubMed ID: 32524305
[TBL] [Abstract][Full Text] [Related]
31. Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis.
Gao X; Overtoom HCG; Eyck BM; Huang SH; Nieboer D; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Chao YK; van Lanschot JJB
Br J Surg; 2024 May; 111(5):. PubMed ID: 38721902
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
33. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.
Korst RJ; Kansler AL; Port JL; Lee PC; Kerem Y; Altorki NK
Ann Thorac Surg; 2006 Aug; 82(2):480-4; discussion 484-5. PubMed ID: 16863749
[TBL] [Abstract][Full Text] [Related]
34. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
36. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
37. The prognostic value of metastatic lymph node number and ratio in oesophageal squamous cell carcinoma patients with or without neoadjuvant chemoradiation.
Chien HC; Chen HS; Wu SC; Hsu PK; Liu CY; Wang BY; Shih CH; Liu CC
Eur J Cardiothorac Surg; 2016 Aug; 50(2):337-43. PubMed ID: 26893382
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
39. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
40. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
